Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Acquired by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc boosted its stake in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 67.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 308,241 shares of the company's stock after buying an additional 124,456 shares during the period. Ensign Peak Advisors Inc owned approximately 0.54% of Structure Therapeutics worth $8,359,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. ANTIPODES PARTNERS Ltd increased its stake in Structure Therapeutics by 115.0% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company's stock worth $28,000 after purchasing an additional 553 shares during the period. GAMMA Investing LLC increased its stake in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company's stock worth $31,000 after purchasing an additional 1,122 shares during the period. FNY Investment Advisers LLC purchased a new stake in shares of Structure Therapeutics during the fourth quarter worth approximately $40,000. Virtus ETF Advisers LLC increased its stake in shares of Structure Therapeutics by 25.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock worth $61,000 after buying an additional 455 shares during the period. Finally, Assetmark Inc. increased its stake in shares of Structure Therapeutics by 72.3% during the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company's stock worth $62,000 after buying an additional 953 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Up 3.0%

GPCR traded up $0.74 on Friday, reaching $25.17. The company's stock had a trading volume of 826,116 shares, compared to its average volume of 934,882. The stock has a 50 day moving average of $21.19 and a two-hundred day moving average of $26.37. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -34.01 and a beta of -1.69. Structure Therapeutics Inc. has a fifty-two week low of $13.22 and a fifty-two week high of $62.74.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on GPCR shares. HC Wainwright cut their target price on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research note on Monday, May 12th. Citigroup started coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 target price on the stock. Finally, William Blair started coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating on the stock. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has an average rating of "Buy" and a consensus price target of $78.00.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.